for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.OQ

Latest Trade

220.06USD

Change

-5.54(-2.46%)

Volume

1,177,168

Today's Range

220.02

 - 

225.49

52 Week Range

215.81

 - 

343.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Biogen Names Alfred Sandrock Vice President, Research And Development

Oct 1 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ANNOUNCES LEADERSHIP UPDATE.BIOGEN INC - ALFRED SANDROCK IS NAMED EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT AND CONTINUES AS CHIEF MEDICAL OFFICER.BIOGEN INC - ALPHONSE GALDES APPOINTED EXECUTIVE VICE PRESIDENT, PHARMACEUTICAL OPERATIONS AND TECHNOLOGY.BIOGEN INC - MICHAEL EHLERS, EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT HAS DECIDED TO LEAVE BIOGEN.

Biogen Names Alfred Sandrock As Executive Vice President, Research And Development And Continues As Chief Medical Officer

Oct 1 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ANNOUNCES LEADERSHIP UPDATE.BIOGEN INC - MICHAEL EHLERS, EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT HAS DECIDED TO LEAVE BIOGEN.BIOGEN INC - ALPHONSE GALDES APPOINTED EXECUTIVE VICE PRESIDENT, PHARMACEUTICAL OPERATIONS AND TECHNOLOGY.BIOGEN INC - ALFRED SANDROCK IS NAMED EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT AND CONTINUES AS CHIEF MEDICAL OFFICER.

Biogen Advances Spinal Muscular Atrophy Clinical Research

Sept 18 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ADVANCES SPINAL MUSCULAR ATROPHY (SMA) CLINICAL RESEARCH WITH NEW STUDY EVALUATING A HIGHER DOSE OF SPINRAZA® (NUSINERSEN) AND ADDITIONAL DATA IN A BROAD RANGE OF PATIENTS.BIOGEN - INITIATION OF NEW TRIAL, DEVOTE TO EVALUATE IF HIGHER DOSE OF SPINRAZA CAN PROVIDE GREATER EFFICACY IN TREATMENT OF SPINAL MUSCULAR ATROPHY.

Samsung Bioepis Announced Expansion Into Brazilian Biopharmaceutical Market

Sept 10 (Reuters) - Biogen Inc <BIIB.O>::SAMSUNG BIOEPIS CO LTD SAYS ANNOUNCED ITS EXPANSION INTO BRAZILIAN BIOPHARMACEUTICAL MARKET; FIRST PRODUCT TO BE AVAILABLE IS BRENZYS.SAMSUNG BIOEPIS - WILL SUPPLY BIOSIMILAR PRODUCTS OR PRODUCT INTERMEDIARIES TO LOCAL PARTNERS FOR SALE TO BRAZIL'S SISTEMA ÚNICO DE SAÚDE FOR 10 YRS.

Biogen Says Diroximel Fumarate Demonstrated Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

July 30 (Reuters) - Biogen Inc <BIIB.O>::DIROXIMEL FUMARATE DEMONSTRATED SIGNIFICANTLY IMPROVED GASTROINTESTINAL TOLERABILITY PROFILE COMPARED TO DIMETHYL FUMARATE IN PATIENTS WITH MULTIPLE SCLEROSIS.BIOGEN INC - DISCONTINUATIONS DUE TO GI EVENTS WERE LESS THAN 1% FOR DIROXIMEL FUMARATE.BIOGEN - DIROXIMEL FUMARATE DEMONSTRATED STATISTICALLY SUPERIOR GI TOLERABILITY COMPARED TO DIMETHYL FUMARATE ON EVOLVE-MS-2 STUDY'S PRIMARY ENDPOINT.BIOGEN INC - BIOGEN INTENDS TO MARKET DIROXIMEL FUMARATE UNDER CONDITIONALLY APPROVED BRAND NAME VUMERITY.BIOGEN INC - OVERALL PROPORTION OF PATIENTS WITH AES LEADING TO STUDY DISCONTINUATION WERE 1.6% FOR DIROXIMEL FUMARATE AND 6.0% FOR DIMETHYL FUMARATE.BIOGEN INC - FURTHER ANALYSIS OF DATA FROM EVOLVE-MS-2 STUDY IS ONGOING AND WILL BE PRESENTED AT A FUTURE SCIENTIFIC FORUM..

Biogen Reports Q2 EPS of $7.85

July 23 (Reuters) - Biogen Inc <BIIB.O>::COMPANY RAISES FULL YEAR 2019 FINANCIAL GUIDANCE.QTRLY EARNINGS PER SHARE $7.85.Q2 2019 REVENUES INCREASED 8% TO $3.6 BILLION.QTRLY ADJUSTED EARNINGS PER SHARE $9.15.2019 REVENUE IS EXPECTED TO BE APPROXIMATELY $14.0 BILLION TO $14.2 BILLION.2019 GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $29.60 AND $30.40.2019 NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $31.50 AND $32.30.Q2 EARNINGS PER SHARE VIEW $7.53, REVENUE VIEW $3.47 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $29.70, REVENUE VIEW $13.95 BILLION -- REFINITIV IBES DATA.QTRLY TECFIDERA REVENUE OF $1,150 MILLION VERSUS $1,087 MILLION REPORTED LAST YEAR.QTRLY TYSABRI REVENUE OF $475 MILLION VERSUS $467 MILLION.QTRLY SPINRAZA REVENUE $488 MILLION VERSUS $423 MILLION.

Skyhawk Therapeutics Says To Expand Collaboration Agreement With Biogen

July 8 (Reuters) - Skyhawk Therapeutics::SKYHAWK THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION AGREEMENT WITH BIOGEN.SKYHAWK THERAPEUTICS, INC - TO EXPAND COLLABORATION WITH BIOGEN TO DEVELOP NOVEL SMALL MOLECULE RNA SPLICING MODIFIERS FOR DISEASE TARGETS.SKYHAWK THERAPEUTICS - BIOGEN TO PAY SKYHAWK ADDITIONAL UPFRONT AND POTENTIAL FUTURE MILESTONE PAYMENTS AND ROYALTIES.

Biogen Announces European Label Update For Spinraza

June 29 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ANNOUNCES EUROPEAN LABEL UPDATE FOR SPINRAZA (NUSINERSEN) WHICH INCLUDES LONGER-TERM DATA ACROSS A BROAD RANGE OF AGES AND TYPES OF SPINAL MUSCULAR ATROPHY.NO NEW SAFETY CONCERNS WERE IDENTIFIED.

Nightstar Therapeutics Plc Court Approval Received In Connection With Acquisition By Biogen

June 5 (Reuters) - Nightstar Therapeutics PLC <NITE.O>::NIGHTSTAR THERAPEUTICS PLC COURT APPROVAL RECEIVED IN CONNECTION WITH ACQUISITION BY BIOGEN.NIGHTSTAR THERAPEUTICS PLC - ALL CONDITIONS TO ACQUISITION HAVE NOW BEEN SATISFIED OR WAIVED.

New Phase 3 Interim Results Support Safety And Efficacy Of Diroximel Fumarate In Multiple Sclerosis

May 30 (Reuters) - Biogen Inc <BIIB.O>::NEW PHASE 3 INTERIM RESULTS SUPPORT SAFETY AND EFFICACY OF DIROXIMEL FUMARATE IN MULTIPLE SCLEROSIS.BIOGEN INC -.BIOGEN INC - DATA SHOW TREATMENT DISCONTINUATIONS DUE TO GASTROINTESTINAL (GI) EVENTS OCCURRED AT A LOW RATE OVER ONE YEAR.BIOGEN INC - DIROXIMEL FUMARATE SIGNIFICANTLY REDUCED DISEASE ACTIVITY IN NEWLY DIAGNOSED RELAPSING MULTIPLE SCLEROSIS (MS) PATIENTS.BIOGEN INC - INTENDS TO MARKET DIROXIMEL FUMARATE UNDER CONDITIONALLY APPROVED BRAND NAME VUMERITY™..BIOGEN INC - DIROXIMEL FUMARATE SIGNIFICANTLY REDUCED DISEASE ACTIVITY IN THOSE PREVIOUSLY TREATED WITH INTERFERONS OR GLATIRAMER ACETATE.BIOGEN- DATA FROM EVOLVE-MS-1 STUDY INDICATE THAT INVESTIGATIONAL TREATMENT DIROXIMEL FUMARATE WAS GENERALLY WELL TOLERATED IN PEOPLE WITH MS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up